T0	Participants 51 77	autism spectrum disorders.
T1	Participants 117 174	subjects diagnosed with an autism spectrum disorder (ASD)
T2	Participants 355 385	subjects diagnosed with an ASD
T3	Participants 456 487	subjects diagnosed with an ASD.
T4	Participants 545 687	trial using oral lipoceutical glutathione (n=13) or transdermal glutathione (n=13) in children, 3-13 years of age, with a diagnosis of an ASD.
T5	Participants 688 742	Subjects underwent pre- and post-treatment lab testing
T6	Participants 1052 1089	oral and transdermal treatment groups
T7	Participants 1371 1401	subjects diagnosed with an ASD